Results 191 to 200 of about 420,448 (359)

Reply to Dr. Vadhithala's Letter to the Editor re: Marc A. Furrer, Benjamin Lyttwin, Michael S. Pärli, et al. Incidental Prostate Cancer Is an Uncommon but Clinically Non-negligible Cause of Death in Selected Long-term Survivors of Urothelial Carcinoma-Oncological Outcomes and a Proposed Follow-up Strategy from a Tertiary Referral Center. Eur Urol Open Sci 2026;86:10-9. [PDF]

Eur Urol Open Sci
Furrer MA, Wuethrich PY, Corcoran NM.
europepmc   +1 more source

Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers

British Journal of Clinical Pharmacology, EarlyView.
Aim Fluorescence‐guided surgery enhances intraoperative visualization of anatomical structures. Nizaracianine is a near‐infrared fluorescent agent that is exclusively renally cleared in animal models. It enables real‐time ureteral imaging and identification, potentially reduces risk of injury and facilitates assessment before surgical closure.
Lisanne K. A. Neijenhuis, Cedric M. W. Pesch, John V. Frangioni, Alexander L. Vahrmeijer, Jacobus Burggraaf, Naomi B. Klarenbeek   +5 more
wiley   +1 more source

Transforming Urological Care With Artificial Intelligence Chatbots: From Digital Assistants to Clinical Partners. [PDF]

Int Neurourol J
Kim EJ, Kim J.
europepmc   +1 more source

Penn clinical manual of urology /

, 2007
Introducing the Penn Clinical Manual of Urology. This one-volume reference presents the key clinical information you need to diagnose and treat urologic disorders quickly and effectively.
Malkowicz, S. Bruce., Hanno, Philip M., Wein, Alan J.   +2 more
core  

Digital diagnostics, biomarkers and therapeutics in an evolving healthcare system: From promise to practice

British Journal of Clinical Pharmacology, EarlyView.
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop, Gertjan J. A. Driessen, Adam F. Cohen, Matthijs D. Kruizinga   +3 more
wiley   +1 more source

Face and content validation of laser enucleation of prostate simulation model: an EAU European School of Urology (ESU) Lower Urinary Tract Endoscopy Working Group study. [PDF]

World J Urol
Sener TE, de Oliveira TR, Demirkiran ED, Perri D, Pereira S, Caballero JP, Osorio L, Kartalas IG, Goossens M, Schoensee B, Dragos L, Veneziano D, Biyani CS, Somani B, Liatsikos E.   +14 more
europepmc   +1 more source

Overcoming intranasal delivery barriers with ultrastable polyzwitterionic siRNA nanocages for enhanced glioblastoma therapy

BMEMat, EarlyView.
A ROS‐responsive, zwitterionic nanocage enables stable, intranasal siRNA delivery to glioblastoma, promoting deep tumor penetration via non‐degradative pathways and trigeminal nerve transport. This platform achieves durable gene silencing and tumor suppression, offering a non‐invasive, storage‐stable strategy for treating glioma and other neurological ...
Jingwen Xie, Jingxing Si, Xiaobei Deng, Jing Tan, Ruijie Zhu, Jizhou Qi, Gaoxia Ma, Bin Wang, Yi Wang, Yunzhou Guo, Yuping Chen, Shiqun Shao, Youqing Shen   +12 more
wiley   +1 more source

Performance of large language models (GPT-5.2, Gemini 3 Pro, Claude Sonnet 4.6 and Grok 4.1) on the Fellowship of The Royal College of Surgeons Urology Part A examination. [PDF]

BMJ Open
Kafagi AR, Atassi N, Kafagi AH.
europepmc   +1 more source

Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy

BMEMat, EarlyView.
This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang, Jiawei Cui, Jin Wang, Manfred F. Maitz, Rifang Luo, Yunbing Wang   +5 more
wiley   +1 more source

What’s Up in Urology Journal, Spring 2011?

Urology Journal, 2011
Urology Journal
doaj